Is the R&D pipeline actually safe this time?

Watching the latest round of cuts in San Diego has me spiraling. Everyone in leadership keeps saying it’s a 'strategic realignment' to focus on high-growth sectors, but we’ve heard that song and dance before. If you look at the sites hit on North Torrey Pines and Mesa Ridge, it feels less like a trim and more like a systematic dismantling of certain long-term research initiatives. My question for those still in the trenches: are you noticing a shift in project priority, or is the company just trying to trim the bottom line to make the quarterly report look prettier for investors? I’m terrified that if we lose more headcount in the life sciences instrumentation group, we’re going to lose our competitive edge entirely. The mood in the office is absolutely toxic right now, and the lack of transparency from management is making it impossible to focus on actual work. I’m currently updating my resume just in case, but I’d like to know if others feel like their specific departments are on the chopping block next.